Brussels, 15/12/2006 (Agence Europe) - In 11 December, the European Commission approved the proposed acquisition of Pfizer's consumer healthcare business (PCH) by Johnson & Johnson (J&J), subject to conditions.
The Commission found that the proposed transaction as initially notified would have given rise to competition concerns in three product areas: topical dermatological antifungals in Italy, daily-use mouthwash in Greece and nicotine replacement therapy (NRT) in the European Economic...